Vorapaxar and Zykadia

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vorapaxar, which is a substrate of the isoenzyme. When vorapaxar was coadministered with ketoconazole 400 mg, mean vorapaxar peak plasma concentration (Cmax) and systemic exposure (AUC) increased by nearly 2-fold. MANAGEMENT: Concomitant use of vorapaxar with potent CYP450 3A4 inhibitors should generally be avoided. References "Product Information. Zontivity (vorapaxar)." Merck & Company Inc, Whitehouse Station, NJ.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vorapaxar, which is a substrate of the isoenzyme. When vorapaxar was coadministered with ketoconazole 400 mg, mean vorapaxar peak plasma concentration (Cmax) and systemic exposure (AUC) increased by nearly 2-fold.

MANAGEMENT: Concomitant use of vorapaxar with potent CYP450 3A4 inhibitors should generally be avoided.

Vorapaxar

Generic Name: vorapaxar

Brand name: Zontivity

Synonyms: n.a.

What is Vorapaxar?

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

What is Zykadia?